TIM3 antibody (APC)

Catalog No. ABIN2658212

The APC-conjugated Rat Monoclonal anti-TIM3 antibody (Clone B8-2C12) (ABIN2658212) specifically detects TIM3 in FACS. The antibody is reactive with Mouse samples.

Quick Overview for TIM3 antibody (APC) (ABIN2658212)

Target: TIM3 (TIM 3) (Hepatitis A Virus Cellular Receptor 2 (TIM 3))

Reactivity: Mouse

Host: Rat

Clonality: Monoclonal

Conjugate: This TIM3 antibody is conjugated to APC

Application: Flow Cytometry (FACS)

Clone: B8-2C12

Product Details anti-TIM3 Antibody (APC)

Purification: The antibody was purified by affinity chromatography and conjugated with APC under optimal conditions. The solution is free of unconjugated APC and unconjugated antibody.

Isotype: IgG1 kappa

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Concentration: 0.2 mg/mL

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Protect from prolonged exposure to light. Do not freeze.

Storage: 4 °C

Storage Comment: The antibody solution should be stored undiluted between 2°C and 8°C.

Target Details for TIM3

Target: TIM3 (TIM 3) (Hepatitis A Virus Cellular Receptor 2 (TIM 3))

Alternative Name: CD366

Target Type: Virus

Background: CD366 (Tim-3) is a transmembrane protein also known as T cell immunoglobulin and mucin domain containing protein-3. Tim-3 is expressed at high levels on Th1 lymphocytes and CD11b+ macrophages. Tim-3 has also been shown to exist as a soluble protein. Cells expressing Tim-3 are present at high levels in the CNS of animals at the onset of experimental autoimmune encephalomyelitis (EAE), a disease mediated by lymphocytes secreting Th1-like cytokines. Tim-3 has been proposed to inhibit Th1-mediated immune responses and promote immunological tolerance.

Pathways: Regulation of Lipid Metabolism by PPARalpha, Cancer Immune Checkpoints